Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells

The Lancet Pub Date : 2025-02-27 DOI:10.1016/s0140-6736(25)00039-x

Daniel J Baker, Bruce L Levine, Carl H June

{"title":"Assessing the oncogenic risk: the long-term safety of autologous chimeric antigen receptor T cells","authors":"Daniel J Baker, Bruce L Levine, Carl H June","doi":"10.1016/s0140-6736(25)00039-x","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Contributors</h2>DJB led the conceptualisation and writing of the original draft. All authors provided comments and edits of subsequent drafts. All authors approved the final manuscript and had final responsibility for the decision to submit for publication.</section></section><section><section><h2>Declaration of interests</h2>BLL is an inventor on patents or has patent applications licensed to Novartis Institutes of Biomedical Research and Kite Pharma and receives licence revenue from such licences; is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics; and is a member of the scientific advisory boards of Avectas, Capstan Therapeutics, Cellula Therapeutics, Immuneel Therapeutics, Immusoft, In8bio, Kite Gilead, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics. CHJ</section></section><section><section><h2>Acknowledgments</h2>This work was supported by the Centurion Foundation Innovation Fund (1P01CA214278, R01CA226983) and the Parker Institute for Cancer Immunotherapy. The funders had no role in the writing of the manuscript or the decision to submit for publication.</section></section>","PeriodicalId":22898,"journal":{"name":"The Lancet","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0140-6736(25)00039-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Contributors

DJB led the conceptualisation and writing of the original draft. All authors provided comments and edits of subsequent drafts. All authors approved the final manuscript and had final responsibility for the decision to submit for publication.

Declaration of interests

BLL is an inventor on patents or has patent applications licensed to Novartis Institutes of Biomedical Research and Kite Pharma and receives licence revenue from such licences; is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics; and is a member of the scientific advisory boards of Avectas, Capstan Therapeutics, Cellula Therapeutics, Immuneel Therapeutics, Immusoft, In8bio, Kite Gilead, Ori Biotech, Oxford Biomedica, ThermoFisher Pharma Services, and UTC Therapeutics. CHJ

Acknowledgments

This work was supported by the Centurion Foundation Innovation Fund (1P01CA214278, R01CA226983) and the Parker Institute for Cancer Immunotherapy. The funders had no role in the writing of the manuscript or the decision to submit for publication.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

The Lancet

自引率

0.00%

发文量